Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review

Journal of Oral and Maxillofacial Pathology

Volumn 16, Issue 2, 2012, Pages 210-214

  Varun, B R ^a   Sivakumar, T T ^a   Nair, Bindu J ^a   Joseph, Anna P ^a  

^a PMS Institute of Dental Science and Research   (India)

Author keywords

Bisphosphonate; breast; cancer; osteonecrosis

Indexed keywords

EID: 84865016897     PISSN: 0973029X     EISSN: 1998393X     Source Type: Journal    
DOI: 10.4103/0973-029X.98893     Document Type: Review

References (30)

1. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
3. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: Long tern follow up of two randomized placebo controlled trials. Cancer 2000;88:1082-90.
4. Jagdev SP, Purohito P, Heatley S, Herling C, Coleman RE. Comparison of the effect of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001;12:1433-38.
5. Marx RE. Pamidronate and zoledronate induced avascular necrosis of jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-17.
6. Sarin J, De Rossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate induced jaw osteonecrosis. Oral Dis 2008;14:277-85.
7. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteoecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-87.
8. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
9. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of intravenous bisphosphonates in patients with skeletal metastasis treated for up to 10 years. Oncologist 2005;10:842-48.
10. Sanna G, Preda L, Bruschini R, Rocca MC, Ferretti S, Adamoli L, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512-16.
11. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-60.
12. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of jaw in patients with multiple myeloma and breast or prostrate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328-32.
13. Ibrahim T, Barbanti F, Marrano GG, Mercatali L, Ronconi S, Vicini C, et al. Osteonecrosis of the jaw in patients with bone metastasis treated with bisphosphonates: A retrospective study. Oncologist 2008;13:330-36.
14. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36.
15. Boonyapakorn T, Schirmer I, Reichert PA, Sturm I, Massenkeil G. Bisphosphonate induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69.
16. Walter C, Al-Nawas B, duBois A, Buch L, Harter P, Grotz KA. Incidence of bisphosphonate associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631-37.
17. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S et al. Bisphosphonate induced osteonecrosis of the jaw:Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112:605-09.
18. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-96.
19. Fleisch H. Bisphosphonates: mechanisms of action. Endocri Rev 1998;19:8-100.
20. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegrin production by primary human Osteoblasts. Biochem Biophy Res Commun 2002;291:680-86.
21. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali FP, Di Cosimo S, et al. Zoledronic acid induced circulating level of modifications of angiogenic factor, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005;69:35-43.
22. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al. American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
23. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-54.
24. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-07.
25. Woo SB, Hellstein JW, Kalmar Jr. Narrative (corrected) review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
26. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42:175-95.
27. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006;137:1144-50.
28. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
29. Sarasquete ME, Gonzalez M, San Miguel JF, Garcia-Sanz R. Bisphosphonate related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009;15:382-87.
30. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate related osteonecrosis of the jaw is associated with polymorphisms of cytochrome P450 CYP2C8 in multiple myeloma: A genome wide single nucleotide polymorphism analysis. Blood 2008;112:2709-12.